Cystic fibrosis is a common genetic condition and abnormal glucose handling leading to cystic fibrosis-related diabetes (CFRD) is a frequent comorbidity. CFRD is mainly thought to be the result of progressive pancreatic damage resulting in beta cell dysfunction and loss of insulin secretion. Whilst Oral Glucose Tolerance Testing is still recommended for diagnosing CFRD, the relationship between glucose abnormalities and adverse outcomes in CF is complex and occurs at stages of dysglycaemia occurring prior to diagnosis of diabetes by World Health Organisation criteria.
INTRODUCTION
Cystic fibrosis (CF) is a common life-limiting autosomal recessive condition with the highest prevalence in populations with Northern European ancestry. The disease is caused by gene mutation causing defective function of a chloride channel-the cystic fibrosis transmembrane conductance regulator (CFTR)-which is vital for mucociliary leads to abnormal glucose levels and progression to cystic fibrosis-related diabetes (CFRD) [2] [3] [4] . The development of glucose abnormalities is recognised to herald a clear increase in morbidity and mortality in patients with CF, leading to a focus on identifying and controlling disordered glucose metabolism in CF [5, 6] .
The management of CFRD is complex and importantly it differs significantly from that of type 1 and type 2 diabetes. Management of CFRD requires a multidisciplinary approach to attempt to ensure the best possible clinical outcome, whilst minimising treatment-associated adverse events. This article explores the pathophysiology, diagnosis and clinical impact of glucose abnormalities in CF and discusses the approach to treatment of this challenging problem.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
PATHOPHYSIOLOGY
CFRD is primarily characterisable as a defect of insulin release resulting from the secretions blocking pancreatic ducts, autodigestion, oxidative stress and destructive fibrotic pancreatic disease that ultimately destroys islet cell function [2] [3] [4] . Pancreatic beta cell function and first phase insulin secretion have been shown to be reduced in CFRD when compared to normal glucose tolerance (NGT) patients with CF where no difference is observed in insulin resistance [7] . Patients with CF also have more rapid small bowel glucose absorption further exacerbating postprandial glucose excursions [8] .
Patients with CF have also been shown to have decreased GLP-1 activity compared to normal controls, which may contribute to glucose abnormalities [9] . CF is a complex multisystem disease, and multiple defects in nutritional status and metabolism also contribute to observed glucose abnormalities. [14] . As patients with CF live longer it is likely therefore that the prevalence of CFRD will increase.
DIAGNOSIS
The onset of CFRD cannot reliably be detected symptomatically, with around 2/3 of patients asymptomatic at diagnosis [15] . [20, 21] . CFRD is additionally associated with a lower than normal red cell lifespan, which could reduce diagnostic utility [22] . In one prospective study an HbA1c of[46 mmol/mol showed a positive predictive value of 50% when compared with OGGT [15] . In another study elevated HbA1c[42 mmol/mol was seen in only 38% of patients with diabetes, confirming a poor sensitivity as a diagnostic test in CFRD [7] . If HbA1c is to have utility, lower levels will need to be considered as clinically important.
An HbA1c C40 mmol/mol has been proposed as a diagnostic level for CFRD screening and is suggested to reduce the need for an OGTT by 50.7% [23] . A systematic review of screening tests for CFRD agreed that the sensitivity of HbA1c is too low to recommended it as a diagnostic test [24] .
Given that pulmonary consequences of CFRD are known to occur when only 1 h postprandial glucose is elevated when measured during an OGTT, there is theoretical merit in using 1 h levels measured by capillary blood glucose (CBG) monitoring or continuous glucose monitoring when performing this investigation [25] [26] [27] [28] .
Our local practice is to recommend annual OGTT for all patients from age 10 years and 1 h postprandial CBG monitoring in patients where clinically indicated by declining lung function, recurrent infection or weight loss. Table 2 shows a summary of diagnostic guidelines. [29] . It has been suggested that an association between poor lung function and dysglycaemia may be more important in females [30] .
IMPACT ON PROGNOSIS
In a UK registry study of 5892 patients with CF the presence of diabetes was an independent risk factor for death (hazard ratio 1.31 (95% CI 1.03-1.67)] [31] . Registry data from the US show that in patients with CF, controlling for other risk factors, diabetes is associated with a 55% increase in 5-year mortality [32] .
These concluded that insulin appears beneficial in CFRD and probably at the IGT stage [24] .
Hypoglycaemia is an obvious potential risk when using insulin in CF patients. were found to be in the hypoglycaemia range (\4.0 mmol/l). Hypoglycaemia was also found to be associated with a significantly higher rate of readmission or death over the 3.5-year follow-up period (P = 0.03) [41] . This is a higher rate of hypoglycaemia than that previously reported in the general population of inpatients with diabetes [42] . Hypoglycaemia in CF patients treated with insulin has also been associated with high levels of loss of awareness of hypoglycaemia, which may reflect loss of glucagon response or high exposure to hypoglycaemic range glucose [38] . It is therefore important to balance the potential benefit of insulin use in CF with the burden and harm of hypoglycaemia.
Continuous subcutaneous insulin infusion
(CSII) by pump would seem in theory to offer significant potential advantages of flexibility and avoidance of hypoglycaemia, which could be of particular benefit in CFRD. Despite this CSII is not commonly used in patients with CFRD, perhaps reflecting increased cost or a feeling that CSII may be too much of a burden to patients already requiring intensive medical intervention [43] .
There have been some small studies of insulin secretagogues showing reductions in glucose levels in CFRD; however none have shown significant benefit to important outcomes of lung function or weight [39, 44] .
We do not presently recommended the use of insulin secretagogues in CFRD. It is our local practice to consider insulin initiation where hyperglycaemia [16, 45] . This seems a reasonable goal, and patients should be encouraged to perform CBG testing regularly including postprandially if possible. Table 3 suggests a guideline for management of glucose abnormalities in CF with insulin.
IMPACT OF OTHER THERAPIES
Nutritional status is of great importance in CF patients who have both increased resting energy expenditure and increased loss of calories through malabsorption and in whom cachexia is known to worsen outcome [46] . Optimising nutritional status is therefore an important goal, which has been shown to improve the ability to undertake normal daily activities [47] .
Patients with CF are therefore recommended to take a high calorie diet (usually 120-150% of the daily recommended intake for age) [16] . To maintain high calorific intake enteral tube feeding (ETF) is commonly utilised and is thought to improve outcome [48] . Schedules for tube feeding vary and take into account the patient's schedule and other treatments, making evidence-based guidelines used in other settings for control of glucose during ETF less applicable [49] . Our experience suggests that liaisoning between the diabetes team and specialist dieticians is crucial when planning ETF. In CF patients ETF is often performed at home and overnight, and timing of feeds can vary from 4-12 h. Variation in the timing and tolerability of ETF can make choosing the optimum insulin to maximise energy conservation from the feed challenging.
Choice of insulin should be made by matching the duration of insulin action to the agreed enteral feeding regimen. Dosing and insulin type can then be altered dependent on CBG readings before, during, and after ETF starts.
Overnight CBG monitoring during ETF will disturb sleep and is therefore particularly burdensome to patients.
Use of steroids (usually prednisolone or methylprednisolone) has been common in patients with CF and can cause transient hyperglycaemia or worsen glucose control in existing CFRD. It has been reported that over 50% of CFRD patients who have been admitted to hospital will have had at least one course of steroid treatment [50] . There is little evidence to guide management of hyperglycaemia related to steroid use in the general population let alone in CFRD. National guidelines suggest enhanced CBG monitoring and the use of insulin to correct hyperglycaemia [51] . We recommend CBG monitoring of fasting and postprandial glucose in all CF patients started on steroids.
SUMMARY
Glucose abnormalities related to CF pose unique challenges to both diabetes and respiratory teams. The close associations between worsening dysglycaemia and poor outcome suggest benefit from insulin replacement therapy, but the time to start treatment and desired CBG levels remain 
